Autres langues Edesa Biotech, Inc.

Actions

EDSA

CA27966L3065

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 07/10/2026			Varia. 5j.	Varia. 1 janv.
3,895 ^USD	+4,70%		+9,41%	+174,30%

19/08	Edesa Biotech lance une offre publique d'actions ordinaires et de bons de souscription	MT
13/08	Edesa Biotech, Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 juin 2026	CI

Autres langues

20/08	Edesa Biotech Announces Pricing of $25.0 Million Public Offering
19/08	Edesa Biotech Launches Public Offering of Common Shares, Warrants
19/08	Edesa Biotech Announces Proposed Public Offering
13/08	Edesa Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026
13/08	Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
16/06	Edesa Biotech, Inc. announced that it has received $3.5 million in funding
11/06	Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
10/06	Edesa Biotech, Inc. announced that it expects to receive $3.5 million in funding
05/06	Top Midday Stories: Lululemon Down After Fiscal Q1 Results; Amazon Engineers Criticize AI Spending; Hoffman to Exit Microsoft Board
05/06	Edesa Biotech Says Paridiprubart Linked to Lower Risk of Death in Acute Kidney Injury Patients
05/06	Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
05/06	Edesa Biotech, Inc. Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
19/05	Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
19/05	Edesa Biotech Inc Presents New Data on Paridiprubart In Acute Kidney Injury
14/05	Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026
14/05	Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
31/03	Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
26/03	Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment
26/03	Edesa Biotech, Inc. Advances Vitiligo Program With Phase 2 Clinical Study of EB06
24/02	Edesa Biotech, Inc. Reports Additional Positive Results from Phase 3 Paridiprubart Study
24/02	Edesa Biotech reports additional results from phase 3 paridiprubart study
24/02	Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
13/02	Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025
13/02	Edesa Biotech Reports Fiscal 1st Quarter 2026 Results
12/12	Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025